Ascendis Pharma reported an initial statement of beneficial ownership for Jan Moller Mikkelsen, a director. Mikkelsen reported direct beneficial ownership of 384,933 ordinary shares. He also reported indirect beneficial ownership of 68,470 ordinary shares held by Cadenza Partners. Mikkelsen reported warrants covering 200,000 ordinary shares at an exercise price of USD 37.18. He also reported restricted stock units covering 15,825 ordinary shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001610717-26-000109), on March 18, 2026, and is solely responsible for the information contained therein.